We report a case of a 63-year-old male with metastatic hepatic PEComa harboring TSC2 and NF2 mutations who achieved a durable partial response to everolimus with only mild adverse effects. This case highlights the value of genomic profiling and the efficacy of mTOR inhibitors in hepatic PEComa management.
Rapid Response, Unexpected Risk: A ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Case with Lazarus Syndrome and Fatal Thrombosis
Asian Medical Journal and Alternative Medicine | April 10, 2026 | Volume: 26 | Issue: 1 | Pages: 56-59
A 57-year-old woman with a ROS1-rearranged NSCLC patient demonstrated a Lazarus response to crizotinib but later developed recurrent pulmonary embolism (PE) with right ventricular (RV) failure. This incident highlights the potential crizotinib-related thrombotic risk and the need for appropriate monitoring of vascular complications, particularly in limited-option settings such as Thailand.